Sucralose and Cardiometabolic Health: Current Understanding from Receptors to Clinical Investigations - INRAE - Institut national de recherche pour l’agriculture, l’alimentation et l’environnement Accéder directement au contenu
Article Dans Une Revue (Article De Synthèse) Advances in Nutrition Année : 2021

Sucralose and Cardiometabolic Health: Current Understanding from Receptors to Clinical Investigations

Résumé

The excess consumption of added sugar is consistently found to be associated with weight gain, and a higher risk of type 2 diabetes mellitus, coronary heart disease, and stroke. In an effort to reduce the risk of cardiometabolic disease, sugar is frequently replaced by low- and null-calorie sweeteners (LCSs). Alarmingly, though, emerging evidence indicates that the consumption of LCSs is associated with an increase in cardiovascular mortality risk that is amplified in those who are overweight or obese. Sucralose, a null-caloric high-intensity sweetener, is the most commonly used LCS worldwide, which is regularly consumed by healthy individuals and patients with metabolic disease. To explore a potential causal role for sucralose in increased cardiovascular risk, this present review summarizes the preclinical and clinical data from current research detailing the effects of sucralose on systems controlling food intake, glucose homeostasis, and gut microbiota.

Dates et versions

hal-03191902 , version 1 (07-04-2021)

Identifiants

Citer

Sydney Risdon, Sylvain Battault, Alonso Romo-Romo, Matthieu Roustit, Loïc Briand, et al.. Sucralose and Cardiometabolic Health: Current Understanding from Receptors to Clinical Investigations. Advances in Nutrition, 2021, 12 (4), pp.1500-1513. ⟨10.1093/advances/nmaa185⟩. ⟨hal-03191902⟩
41 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More